Tril­li­um is hunt­ing gi­ants with its an­ti-CD47 drug, but ques­tions over a high-dose so­lo reg­i­men still linger

CD47 play­er Tril­li­um Ther­a­peu­tics re­leased a new slate of da­ta for two of its ex­per­i­men­tal can­cer drugs on Wednes­day, up­dat­ing pre­vi­ous­ly re­leased re­sults from last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER